Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Peptilogics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Peptilogics’ Nautilus™ platform enables in silico predictive peptide design across diverse targets to efficiently access new functional chemical space and custom design therapeutics.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 07, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Peptilogics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Darolutamide,Undisclosed
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Orion and Bayer Expand Development Program for Darolutamide in Prostate Cancer
Details : Nubeqa (darolutamide) is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of pros...
Product Name : Nubeqa
Product Type : HPAPI
Upfront Cash : Inapplicable
August 02, 2021
Lead Product(s) : Darolutamide,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OB-002
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Phase 1 study design included open-label single-dose (vaginal and rectal) and multi-dose product (vaginal) administration of OB-002H gel to study participants followed by a randomised, double-blind, placebo-controlled multi-dose (vaginal) phase of pr...
Product Name : OB-002
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 15, 2020
Lead Product(s) : OB-002
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OB-002
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : National Research Council Industrial Research Assistance Program
Deal Size : Undisclosed
Deal Type : Funding
Orion Biotechnology Receives Funding to Test OB-002 for Treatment of COVID-19
Details : Funding from the National Research Council Industrial Research Assistance Program will support the development of Orion’s lead compound, OB-002, a promising treatment for SARS-CoV-2 infection associated acute respiratory distress syndrome (ARDS).
Product Name : OB-002
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 30, 2020
Lead Product(s) : OB-002
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : National Research Council Industrial Research Assistance Program
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Levosimendan
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The primary endpoint of the trial was to show a statistically significant difference between levosimendan and placebo in slow vital capacity (SVC) in supine position at 12 weeks compared to the baseline.
Product Name : ODM-109
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 28, 2020
Lead Product(s) : Levosimendan
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Bayer AG
Deal Size : $31.3 million
Deal Type : Agreement
Orion Receives Total of EUR 28 Mllion Milestones From Bayer For Sales of Darolutamide
Details : The transaction follows the Sales of Nubeqa® (darolutamide), jointly developed by Orion Corporation and Bayer for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC), started in the EU and Japan.
Product Name : Nubeqa
Product Type : HPAPI
Upfront Cash : Undisclosed
May 20, 2020
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Bayer AG
Deal Size : $31.3 million
Deal Type : Agreement
Lead Product(s) : 0B-002
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Phase 1 study was a first-in-man trial designed to evaluate the safety, acceptability, and pharmacokinetic profile of OB-002H gel which is being developed for a HIV prevention indication.
Product Name : 0B-002
Product Type : Protein
Upfront Cash : Inapplicable
April 30, 2020
Lead Product(s) : 0B-002
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The approval is based on Phase III ARAMIS trial results showing a statistically significant improvement in metastasis-free survival (MFS) for darolutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT, and a favorable safety profile.
Product Name : Nubeqa
Product Type : HPAPI
Upfront Cash : Inapplicable
March 30, 2020
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Results from Phase III ARAMIS trial that investigated Nubeqa (darolutamide) in men with nMCRC, show a statistically significant improvement in overall survival in patients receiving darolutamide plus androgen deprivation therapy compared to placebo plus ...
Product Name : Nubeqa
Product Type : HPAPI
Upfront Cash : Inapplicable
January 30, 2020
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Marketing Authorization Granted for Darolutamide in Japan
Details : Approval is based on Phase III ARAMIS trial showing a highly significant improvement in primary efficacy endpoint of metastasis-free survival, with a median 40.4 months for Nubeqa (darolutamide) plus ADT versus 18.4 months for placebo plus ADT.
Product Name : Nubeqa
Product Type : HPAPI
Upfront Cash : Inapplicable
January 23, 2020
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
